Tag: Kyle Holen

Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma

Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative ... Read More